ALUMIS INC.(ALMS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,948 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ALMS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ALUMIS INC. (ALMS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALMS at 7.1/100 on a 32-signal composite quality model, placing it at rank #2,948 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.7) and profitability (0.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ALUMIS INC. reports quarterly revenue of $1.7M, net income of $-142.2M, free cash flow of $-81.7M. Top institutional holders of ALMS by reported 13-F value include AyurMaya Capital Management Company, BlackRock, FMR, based on the most recent SEC filings. ALMS trades on the Nasdaq exchange and files with the SEC under CIK 1847367. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALMS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALUMIS INC. directly from SEC EDGAR. ALUMIS INC.'s 13F Pro composite quality score has ranged between 6 and 8 since 2026, currently 7.1 — a stable long-term trajectory across 27 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.7M
Net Income
Q2 2026
$-142.2M
Free Cash Flow
Q2 2026
$-81.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+17.3% YoYOperating Income
-50.9% YoYEPS (Diluted)
+72.4% YoYTotal Assets
+20.8% YoYOp. Cash Flow
-44.9% YoYFree Cash Flow
-44.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $24.1M | — | — | — |
| Net Income | $-243.3M +17.3% | $-294.2M -89.8% | $-155.0M | — |
| Operating Income | $-453.8M -50.9% | $-300.8M -90.1% | $-158.2M | — |
| EPS (Diluted) | $-2.86 +72.4% | $-10.38 +85.6% | $-72.08 | — |
| Total Assets | $411.9M +20.8% | $341.0M +280.5% | $89.6M | — |
| Operating Cash Flow | $-369.5M -44.9% | $-255.1M -96.3% | $-130.0M | — |
| Free Cash Flow | $-370.2M -44.1% | $-256.8M -91.0% | $-134.5M | — |
Get alerted when ALMS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ALUMIS INC. including:
Top Institutional Holders of ALMS
AyurMaya Capital Management Company, LP
$426.0M15,139,707 shBlackRock, Inc.
$231.3M8,218,151 shFMR LLC
$190.5M6,769,170 shDeep Track Capital, LP
$178.6M6,348,558 shSamsara BioCapital, LLC
$178.6M6,345,219 shForesite Capital Management V, LLC
$165.9M5,896,995 shPRICE T ROWE ASSOCIATES INC /MD/
$146.3M5,199,838 shvenBio Partners LLC
$127.4M4,528,408 shForesite Capital Management VI LLC
$119.5M4,247,670 shVANGUARD CAPITAL MANAGEMENT LLC
$118.6M4,215,703 sh
| Fund | Value | Shares |
|---|---|---|
| AyurMaya Capital Management Company, LP | $426.0M | 15,139,707 |
| BlackRock, Inc. | $231.3M | 8,218,151 |
| FMR LLC | $190.5M | 6,769,170 |
| Deep Track Capital, LP | $178.6M | 6,348,558 |
| Samsara BioCapital, LLC | $178.6M | 6,345,219 |
| Foresite Capital Management V, LLC | $165.9M | 5,896,995 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $146.3M | 5,199,838 |
| venBio Partners LLC | $127.4M | 4,528,408 |
| Foresite Capital Management VI LLC | $119.5M | 4,247,670 |
| VANGUARD CAPITAL MANAGEMENT LLC | $118.6M | 4,215,703 |
Companies Similar to ALMS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Monte Rosa Therapeutics, Inc.
Silence Therapeutics plc
CytomX Therapeutics, Inc.
Entrada Therapeutics, Inc.
Celldex Therapeutics, Inc.
BioAge Labs, Inc.
Dianthus Therapeutics, Inc. /DE/
Zymeworks Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ALMS on your watchlist
Track score changes the day ALUMIS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ALMS a good stock to buy?
13F Pro's AI-powered analysis of ALUMIS INC. (ALMS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALMS are available on the ALMS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ALMS is classified as a mid company.
Which hedge funds own ALMS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALMS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ALUMIS INC.'s investment landscape.